We read with great interest the results of the phase II clinical trial on infliximab in refractory uveitis.1 We congratulate Dr Suhler and colleagues on emphasizing pretreatment screening and the potential systemic complications.
Contrary to previous descriptions of tumor necrosis factor (TNF) α inhibitors for refractory uveitis,2 it is implied that the stringent investigations and observations in this study projected more systemic complications leading to cessation of therapy in 50% of the patients. Some of the described complications may suggest preexisting risk factors or even an unrelated occurrence.
Sebastian RT, Harding SP, Bucknall RC, Pearce IA. Optimizing the Use of Tumor Necrosis Factor α Inhibitors in Refractory Uveitis. Arch Ophthalmol. 2006;124(10):1505. doi:10.1001/archopht.124.10.1505-a